ClinicalTrials.gg
SuspendedNCT05028621Updated Oct 6, 2026

Molecular Basis of Langerhans and Non-Langerhans Cell Histiocytic Neoplasms and Castleman Disease

An interventional study of Genetic testing in Castleman's Disease (CD), Langerhans Cell Histiocytosis (LCH) and Non-Langerhans-Cell Histiocytosis, sponsored by Case Comprehensive Cancer Center. Suspended at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Case Comprehensive Cancer Center · Not applicable, Interventional, and Screening

How we know

Why this study was suspended
Working on changing study vendor
Updated Oct 6, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
135
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 14 studies in Castleman Disease with a site in United States — 4 open to participants now, 5 under way, none of them phase 3. Castleman Disease · United States.

Started
2021
the only one that year
No phase
Only one
of the 14
Registered
13th of 14
by date
Lead sponsor
1 of 14
Case Comprehensive Cancer Center

Among the 14 studies in Castleman Disease with a site in United States, this one is the only one that started in 2021, is the only one with no phase, and was the 13th registered.

Castleman Disease

22 studies on the registry are indexed under Castleman Disease; 9 are open to participants now.

Browse Castleman Disease studies →

Open to participants now

4 of the 14 studies in Castleman Disease with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 8 Castleman Disease studies recruiting now, 7 set no upper age limit and none stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Castleman Disease with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to use agnostic genomic evaluation using whole exome sequencing (WES) of a variety of rare hematologic diseases grouped under rare blood diseases and its variants to further elucidate the understanding of the chemistry of these disorders and identify potential actionable mutations that can be targeted with therapies in the context of clinical trials.

Read the detailed description

The study team will examine genetic changes, also known as mutations, in the DNA of participants' blood, or if applicable, bone marrow specimen. These types of tests are increasingly used by doctors to improve the accuracy of diagnosis and make decisions during care. This study seeks to understand how many patients will benefit from this testing, and in what ways. The results of this portion of the study are placed in the individual's medical record and are communicated back to each participant.

03

Conditions studied

  • Castleman's Disease (CD)
  • Langerhans Cell Histiocytosis (LCH)
  • Non-Langerhans-Cell Histiocytosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have histopathologic confirmation of the particular rare hematologic disease.
  • Diseases that will be considered as rare hematologic diseases for this study will include the following

    • Langerhans cell histiocytosis (LCH)
    • Erdhiem Chester disease (ECD)
    • Rosai-Dorfman disease (RDD)
    • Miscellaneous histiocytic entities -indeterminate dendritic cell tumor, interdigitating dendritic cell sarcoma, follicular dendritic cell sarcoma, fibroblastic reticular cell tumor
    • Unicentric Castleman disease
    • Multicentric Castleman disease including TAFRO
    • Follicular Dendritic Cell sarcoma (FDCS)
  • Newly diagnosed treatment naïve patients as well as patients who received prior therapies (e.g. chemotherapy, targeted therapy, surgery, or radiation) will be included. -Tissue specimens collected within the past 5 yearse will be considered acceptable for study inclusion will include the following
  • Collected as part of the evaluation for diagnostic confirmation
  • Tissue specimen or extracted DNA (from blood sample) banked in IRB approved tissue repositories and obtained within five years prior to the date of . -Tissue samples are planned to be collectedfrom previously stored surgical specimens already being stored in pathology lab
  • Consent to have germline testing performed in parallel to tumor testingg)Patients willing to receive treatmen

Exclusion criteria

Exclusion Criteria:

  • of less than 6months
  • Patient unwilling to have germline testing performed on peripheral blood or buccal mucosa
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
135 participants (estimated)

Study arms

  • Experimental
    Genomic analysis

    When a participant's disorder was diagnosed, blood or tissue specimen was collected. A part of the tissue or blood will be sent to an outside company, Tempus, to be tested for specific genetic changes and the results will be sent back to participants' physician.

    Diagnostic Test: Genetic testing

Interventions

  • Diagnostic testGenetic testing

    Genetic testing of blood or tissue sample and limited medical information sent to an outside company. Database will link genome sequence data with human trait information, including cancer and other diseases, to be sent to participant's physician.

06

What researchers measure

Primary outcomes

  1. Proportion of genomic analyses yielding genetic aberrations

    Proportion of genomic analyses yielding actionable genetic aberrations. "Actionable" is defined as a mutation linked to an approved therapy in the particular disease under study or another disease, a known or suspected contraindication to a given therapy, or a clinical trial linked to the alteration

    Time frame: Up to 12 months from last participant accrued

Secondary outcomes

  1. Proportion of genomic analyses yielding actionable genetic aberrations

    Actionable will be defined as a mutation linked to an approved therapy in the particular disease or another disease, a known or suspected contraindication to a given therapy, or a clinical trial linked to the alteration.

    Time frame: Up to 12 months from last participant accrued

  2. Proportion of genomic analyses yielding germline genetic aberrations

    Time frame: Up to 12 months from last participant accrued

  3. Referral rates for genetic counseling for germline mutations

    Number of participants with germline mutations who were referred to genetic counseling through Cancer Genetics for their identified germline mutations

    Time frame: Up to 12 months from last participant accrued

  4. Completion rates of genetic counseling for germline mutations

    Number of participants with germline mutations who were referred to, and underwent (completed) genetic counseling through Cancer Genetics.

    Time frame: Up to 12 months from last participant accrued

07

Study locations

1 site
  • Cleveland Clinic, Case Comprehensive Cancer Center
    Cleveland, Ohio 44106-5065, United States
08

References and documents

Individual participant data

Plan to share: Yes — Deidentified IPD will be shared to maintain patient confidentiality

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jun 2021 (actual). Primary completion is estimated for Jan 2027, 67 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 6, 2026: primary completion Sep 2026 → Jan 2027 and completion Sep 2026 → Jan 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2021
First posted
Aug 31, 2021
StartActual
Jun 18, 2021
Primary completionEst.
Jan 2027was Sep 2026
CompletionEst.
Jan 2027was Sep 2026
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 2026→Jan 2027
Oct 6, 2026
Study completion
Sep 2026→Jan 2027
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Primary completion Sep 2026→Jan 2027
    Study completion Sep 2026→Jan 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05028621
Responsible party
Sponsor
First posted
Aug 31, 2021
Start date
Jun 18, 2021
Primary completion
Jan 2027 (estimated)
Completion
Jan 2027 (estimated)
Last update
Oct 6, 2026

Study contacts

Sudipto Mukherjee, MD, PhD
principal investigator · Cleveland Clinic, Case Comprehensive Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is suspended, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion